MedTrace Logo

Ivermectin and Human Immunity

NCT03459794 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-07-12

Study results available
· View outcomes & findings →

Summary

We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.

Conditions

  • Ivermectin

Interventions

DRUG

Ivermectin

150 mcg/kg ivermectin, by mouth.

OTHER

Placebo

An oral placebo will be administered, once

Sponsors & Collaborators

  • University of Georgia

    lead OTHER

Principal Investigators

  • Adrian J Wolstenholme, PhD · University of Georgia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-12
Primary Completion
2018-04-09
Completion
2018-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03459794 on ClinicalTrials.gov